

Index

- acetylation of histones 56–57
- aciclovir 283, 285
- acrocytosis 193–194
- activin-A 101, 104
- acute kidney injury (AKI) 255, 261–262, 268
- acute myeloid leukemia 12
- adhesion molecules 65, 68–71
- adriamycin 151
- age
- at diagnosis 2
 - treatment options 134
- AKI (acute kidney injury) 255, 261–262, 268
- Akt signaling pathway 72–74, 77, 112–113
- AL amyloidosis *see* amyloidosis, primary
- alemtuzumab 14, 201
- allogeneic stem cell transplantation 137, 155
- CMV infection 283
 - graft-versus-myeloma effect 91–92, 283
 - in Waldenstrom macroglobulinemia 205–206
- amyloidosis
- in extramedullary plasmacytoma 21
 - primary (AL amyloidosis) 174–185
 - bleeding abnormalities 184
 - diagnosis 22, 174–176, 259
 - epidemiology 174
 - GI tract 183
 - heart 176–179, 181
 - kidney 176–177, 181–183, 258–259
 - liver and spleen 176–177, 183
 - lung 184
 - peripheral nerves 176–177, 183–184, 246
 - prognosis 22, 175–178, 246
 - treatment 178–181, 183–185
 - transthyretin (ATTR) 174
 - in Waldenstrom macroglobulinemia 195–196
- anakinra 130, 236
- anemia
- γ -HCD 239
 - POEMS syndrome 227
 - Waldenstrom macroglobulinemia 194–197
- angiogenesis 68, 113, 124, 217–218
- ANP32E overexpression 52
- antibiotics 277–279
- in α -HCD 238
 - prophylactic 84, 92, 285
- antifungal agents 279–282
- prophylactic 285
- antigen-presenting cells
- dendritic cells/macrophages 69–70, 88, 92
 - myeloma cells 90
- antiviral agents
- HAART 222
 - for HCV 233
 - for herpes viruses 221, 283
 - prophylactic 285
- apoptosis signaling pathways 68, 71–72, 87, 113
- APRIL (a proliferation-inducing ligand) 67–68, 71, 88
- ASCT *see* autologous stem cell transplantation
- Aspergillus* infections 279–281, 285
- asymptomatic myeloma *see* smoldering myeloma
- atacept 68
- ataxic neuropathy 194
- ATTR (transthyretin) amyloidosis 174
- autoantibody activity
- Castleman's disease 218
 - peripheral neuropathy 193–194, 230, 245–246
 - Waldenstrom macroglobulinemia 193–195
- autologous stem cell transplantation (ASCT)
- amyloidosis 178–180
 - cryoglobulinemia 233–234
 - de novo* myeloma 135–137
 - infection risk 277
 - POEMS syndrome 229–230
 - primary refractory myeloma 154–155
 - prognostic value of MRD 13–14
 - in relapsed myeloma 145, 155
 - in renal disease 266–268
 - in Waldenstrom macroglobulinemia 199, 205
- autonomic neuropathy 245–246
- thalidomide-induced 247
- Avastin (bevacizumab) 113, 230
- B cell receptor signaling pathway (Btk) inhibition 116
- bacterial infections 84–86, 277–279, 285
- BAFF (B-cell activating factor) 67, 71, 88
- Bence Jones proteinuria 196, 238
- bendamustine 155–156, 202, 204
- bevacizumab (Avastin) 113, 230
- Bing-Neel syndrome 195
- bisphosphonates 101–103
- anti-tumor effect 88, 91, 102
 - in MGUS 125
 - nephrotoxicity 103, 261
 - in smoldering myeloma 129
- black ethnic groups 6, 124
- blood abnormalities
- amyloidosis 184
 - γ -HCD 239
 - POEMS syndrome 227
 - Waldenstrom macroglobulinemia anemia 194–197
 - hyperviscosity syndrome 191–193, 196, 200
- bone disease
- clinical presentation 96
 - in MGUS 125
 - osteomyelitis 276
 - osteosclerosis 29, 228
 - pathophysiology 96–101
 - treatment 101–104, 115–116
- bone marrow (BM)
- cellular environment 64
 - cellular interactions 69–70, 191
 - hypoxia 70
 - migration of myeloma cells 64–65
 - signaling pathways 66–68, 70–77
 - soluble factors 64–69, 86–88, 112, 124
 - cellular features 11–13
 - amyloidosis 22
 - extramedullary plasmacytoma 21

- γ-HCD 239
 IgM myeloma 15
 MGUS 11, 19
 minimal residual disease 13–14
 on MRI 31–32
 POEMS syndrome 23, 228
 solitary bone plasmacytoma 20
 Waldenstrom macroglobulinemia
 23–24, 191, 196–197
 bone marrow stromal cells (BMSCs)
 69, 71
 bortezomib (Velcade) 114
 amyloidosis 180
 bone disease 104
 de novo myeloma
 consolidation post-ASCT 139
 induction pre-ASCT 134–135
 induction without ASCT 137
 maintenance post-ASCT 140
 maintenance without ASCT 140
 plus a CDK inhibitor 42
 extramedullary plasmacytoma 171
 mode of action 69, 72, 91, 151, 262
 peripheral neuropathy and 248–249
 pharmacokinetics 262
 relapsed myeloma 148–149,
 151–154
 novel combination therapies
 156–157
 renal disease 262–264
 viral infection risk 84, 276–277
 Waldenstrom macroglobulinemia
 201, 203–204
 BRAF/BRAF
 inhibitors 74, 111
 mutations 54
 brentuximab 114
 Bruton's tyrosine kinase (Btk)
 inhibition 116

 N-cadherin 65
Campylobacter jejuni infections 238
 cancer registries 1–2
 cancer testis antigens 90, 92
Candida infections 279–280, 285
 cardiac disorders
 amyloidosis 176–179, 181
 autonomic neuropathy 245, 247
 carfilzomib (Kyprolis) 114, 157, 248,
 268
 cast nephropathy 256–259, 261–262,
 268
 Castleman's disease 216–222
 in POEMS syndrome 228
 β-catenin 104
 CD antigens
 adhesion receptors 65, 68–69
 B cells as myeloma precursor cells
 43–44
 extramedullary plasmacytoma 21
 IgM myeloma 15
 MGUS 19
 myeloma 11–13
 plasma cell leukemia 14
 solitary bone plasmacytoma 20
 t(11;14) myeloma 15
 Waldenstrom macroglobulinemia
 24, 191, 196
 CD4+/CD8+ T cells 88
CDKN2C (p18) 41, 52
 CDKs (cyclin-dependent kinases)
 39–40, 42
 cell cycle control
 in myeloma 40–42
 in normal cells 39–40
 therapeutic targets 42
 cerebrospinal fluid (CSF) 282
 chemokines 64–65, 99
 chemotherapy, conventional
 and bisphosphonates 102
 Castleman's disease 220
 de novo myeloma 134, 139
 relapsed/refractory myeloma
 145–146
 Waldenstrom macroglobulinemia
 198–200
 see also corticosteroids
 (dexamethasone, prednisone);
 immunomodulatory drugs
 (lenalidomide, pomalidomide,
 thalidomide); melphalan;
 monoclonal antibody
 therapies; *proteasomal*
 inhibitors (bortezomib,
 carfilzomib)
 chemotherapy-induced peripheral
 neuropathy (CIPN) 246–251
 chest infections 276–278, 280–282
 chlorambucil 198–199
 chromosomal abnormalities
 see cytogenetics
 chronic kidney disease (CKD) 255,
 261–268
 cisplatin combination therapies 139,
 146, 153
 CKIs (cyclin-kinase inhibitors) 39–41,
 52
CKS1B/CKS1B overexpression 41,
 52
 cladribine 199–200, 203
 clarithromycin 202
 classification 1–2
 clinical features
 amyloidosis in various organs
 176–177, 181–184
 bone disease 96
 Castleman's disease 216, 219–220
 and choice of therapy 144–145
 cryoglobulinemia 232–233
 extramedullary plasmacytoma 21,
 170
 Fanconi syndrome 237–238,
 259–260
 fibrillary glomerulonephritis 238
 heavy chain disease
 α-HCD 238
 γ-HCD 238–239
 μ-HCD 239
 LCDD 237
 MGUS neuropathy 230
 necrobiotic xanthogranuloma
 235
 peripheral neuropathy 245–246
 assessment and grading 249
 chemotherapy-induced
 247–248
 POEMS syndrome 29, 226–228
 Schnitzler syndrome 236
 scleromyxedema 234
 solitary bone plasmacytoma 167,
 191–197
 Waldenstrom macroglobulinemia
 191–197
 see also imaging
 clodronate 101
Clostridium difficile infection 278
 CMV (cytomegalovirus) 283, 285
 co-trimoxazole 84, 282, 285
 coagulopathy in amyloidosis 184
 cold agglutinin hemolytic anemia
 194–195
 computed tomography (CT) 29–31,
 36–37
 aspergillosis 280
 Waldenstrom macroglobulinemia
 197
 see also FDG PET/CT imaging
 contrast media 31
 copy number alterations 51–53
 corticosteroids 220
 see also dexamethasone; prednisone
 Cox-2 (cyclooxygenase-2)
 overexpression 87
 creatinine 255
 CRM1 (nuclear export protein)
 inhibition 116–117
 Crow-Fukase syndrome *see* POEMS
 syndrome
 cryoglobulinemia 193, 232–234, 246
Cryptococcus infections 282
 CT *see* computed tomography
 cyclin D1/D2/D3
 in cell cycle control 39, 42
 overexpression in myeloma 40, 50
 plasma cell immunophenotype (D1)
 12, 15
 as therapeutic targets 42

Index

- cyclin-dependent kinases (CDKs)
 39–40, 42
 cyclin-kinase inhibitors (CKIs) 39–41,
 52
 cyclophosphamide combination
 therapies
 amyloidosis 179
 Castleman's disease 220
 de novo myeloma 139
 relapsed/refractory myeloma 146,
 150–151, 153
 Waldenström macroglobulinemia
 202–203
CYLD deletion 53–54
 cytogenetics
 acute myeloid leukemia 12
 amyloidosis 22, 175
 extramedullary plasmacytoma 21
 MGUS 25, 124
 myeloma
 pathogenesis 41–45, 49–53, 124
 phenotype–genotype correlations
 12–13, 15
 prognosis 41, 52–53, 144, 175
 treatment responses 151–152
 plasma cell leukemia 14
 POEMS syndrome 23
 Waldenström macroglobulinemia
 24–25, 190–191
 cytokines 65–69
 and bone disease 99–101
 and the immune system 86–89
 see also individual molecules
 cytomegalovirus (CMV) 283, 285
- dalotuzumab 114
 daratumumab 114
de novo myeloma 134
 consolidation post-ASCT 139
 induction pre-ASCT 134–137,
 140–141
 induction without ASCT 137–139,
 141
 maintenance post-ASCT 139–140
 maintenance without ASCT
 140–141
 risk stratification 134
 decorin 104
 del(1p) 52
 del(6q) 53, 190–191
 del(12p) 52
 del(13) 53
 del(16q) 53
 del(17p) 52–54
 dendritic cells (DCs) 69–70, 88, 92
 Castleman's disease 218
 denosumab 103, 115
 dermatological conditions *see* skin
 conditions
- dexamethasone
 adverse effects 145, 276
 amyloidosis 178–180
 de novo myeloma
 consolidation post-ASCT 139
 induction pre-ASCT 134–135
 myeloma-associated renal disease
 262
 POEMS syndrome 229
 relapsed myeloma
 monotherapy 145
 plus bortezomib 152–154
 plus lenalidomide 150–151, 153–154
 plus pomalidomide 156
 plus thalidomide 148–150,
 153
 Waldenström macroglobulinemia
 202–204
 diagnosis 11–13
 amyloidosis 22, 174–176, 259
 Castleman's disease 216–218
 CMV infection 283
 extramedullary plasmacytoma 21,
 170
 fungal infections 279–282
 IgM myeloma/MGUS 15, 24–25
 imaging 28–37
 immunophenotyping 11–12
 LCDD 259
 MGUS 11–12, 19, 32, 121
 necrobiotic xanthogranuloma 235
 plasma cell leukemia 14–15
 POEMS syndrome 23, 226–228
 renal disease 255, 259–260
 Schnitzler syndrome 236
 scleromyxedema 234
 smoldering myeloma 121, 125
 solitary bone plasmacytoma 20, 32,
 167–168
 t(11;14) myeloma 15
 Waldenström macroglobulinemia
 23–24, 196–197
 dialysis
 removal of free light chains 261–262
 renal replacement therapy 262
 diarrhea 183
 dietary supplements 250
 diffuse large B-cell lymphoma
 (DLBCL) 25
 diffusion weighted imaging (DWI)
 32–33
 dimorphic fungi 282–283
 dinaciclib 158
DIS3 mutations 54
 diuretics 181
 Dkk-1 (*dickkopf-1*) 100, 103–104,
 115–116
 DLBCL (diffuse large B-cell
 lymphoma) 25
- DNA methylation 55, 58–60
 doxorubicin
 and bisphosphonates 102
 Castleman's disease 220
 relapsed myeloma 150, 152–154
 Waldenström macroglobulinemia
 202–203
 drug resistance 65, 68–72
 drug-induced injury
 nephrotoxicity 103, 261
 neuropathy 246–251
- elderly patients
 epidemiology 2
 not eligible for ASCT
 induction chemotherapy
 137–139, 141
 maintenance chemotherapy
 140–141
 electrophoresis (in renal disease)
 259
 elotuzumab 14, 158
 EMP (extramedullary plasmacytoma)
 21, 170–171
 see also solitary bone plasmacytoma
 endocrinopathies in POEMS
 syndrome 227–228
 ENMZL (extranodal marginal zone
 lymphoma) 21
 environmental risk factors 7–8, 190
 epidemiology 1–8
 amyloidosis 174
 cryoglobulinemia 232
 MGUS 2, 4, 6–8, 48, 122, 124–125
 solitary plasmacytomas 167, 170
 Waldenström macroglobulinemia
 190
 epigenetics 55–60
 Epstein-Barr virus 25
 ERK1/2 signaling pathway(s) 77,
 112–113
 inhibitors 110–111
 erythrocyte sedimentation rate 196
 ethnicity 6, 124
 etiology 6–8, 190
 etoposide
 Castleman's disease 222
 myeloma 139, 146, 153
 everolimus 113, 202
 extramedullary plasmacytoma (EMP)
 21, 170–171
 see also solitary bone plasmacytoma
 extranodal marginal zone lymphoma
 (ENMZL) 21
- eye
 necrobiotic xanthogranuloma 235
 POEMS syndrome 226
 Waldenström macroglobulinemia
 193, 195–196

- factor X deficiency 184
FAF1 deletion 52
FAM46C deletion/mutation 52, 54
 family history 7, 124–125, 190
 Fanconi syndrome 237–238, 258–260
 farnesyl pyrophosphate synthase (FPP synthase) inhibition 102
 farnesyltransferase inhibitors 74
 Fas/FasL pathway 87
 FDA-approved targeted therapies 110–111, 114
 FDG PET/CT imaging 34, 37
 plasmacytoma 168, 170
FGFR3/FGFR3 (fibroblast growth factor receptor-3)
 overexpression 40–41, 50
 fibrillary glomerulonephritis 238
 flow cytometry
 diagnosis 11–12, 22
 prognosis 12–14, 19–20
 fluconazole 279, 282, 285
 fludarabine 199–200, 203
 fludrocortisone 181
 follicular dendritic cells 218
 foscarnet 283
 fotemustine 146
 fractures
 imaging 31–32, 97
 risk in MGUS 125
 fundoscopy 193, 196
 fungal infections 279–283, 285
Fusarium infections 281
- gain(1q) 41, 52
 gain(5q) 52
 $\gamma\delta$ T cells 88, 91
 ganciclovir 283, 285
 ganglioside autoantibodies 193–194
 gastrointestinal tract
 in α -HCD 238
 in amyloidosis 183
 in Waldenstrom
 macroglobulinemia 195
 geldanamycin 77
 gender 2, 4–5
 gene expression profiling (GEP) 55, 124
 genetics/genomics
 CIPN susceptibility 248–249
 pathogenesis 49–55, 124, 190
 response to rituximab 200–201
 risk factors 7, 124–125
 Waldenstrom macroglobulinemia 190, 200–201
 see also cytogenetics
 geographical trends in incidence 4–6
 glomerular filtration rate (GFR) 255
 glomerulonephritis 238
- graft-versus-myeloma effect 91–92, 283
 GSK3 signaling pathway 74–75
- HAART (highly active anti-retroviral therapy) 222
Haemophilus influenzae infection 278
 HCD see heavy chain disease
 HDACs (histone deacetylases) 56–57
 inhibitors 56–57, 116, 156–157
 heart see cardiac disorders
 heat shock protein 90 (Hsp90) 77, 113
 heavy chain disease (HCD) 238, 258–259
 α -HCD 238
 γ -HCD 238–239
 μ -HCD 239
 helminthic infestations 284
 hemolytic anemia 194–197
 hepatic disease
 amyloidosis 176–177, 183
 cryoglobulinemia 233
 hepatitis viruses 284
 HCV in cryoglobulinemia 232–233
 hepatocyte growth factor (HGF) 68, 100
 herpes viruses 283–285
 HHV8 in Castleman's disease 218–219, 221
 HGF (hepatocyte growth factor) 68, 100
 histone acetylation 56–57
 histone deacetylase (HDAC)
 inhibitors 56–57, 116, 156–157
 histone methylation 57–58
 HIV (human immunodeficiency virus) 219–220, 222
 homing of myeloma cells (into BM) 64–65
 Hsp90 (heat shock protein 90) 77, 113
 human herpesvirus 6 (HHV6) 283–284
 human herpesvirus 8 (HHV8) 218–219, 221
 hyaline vascular variant of
 Castleman's disease 217–218
 hypercalcemia 261
 hyperdiploidy 49–51
 DNA methylation patterns 60
 hyperviscosity syndrome 191–193, 196, 200
 hypogammaglobulinemia 89
 hypoxia in the BM 70
- ibrutinib 116
 idarubicin 145
 idiotype (Id) 90, 92
 IFN- α (interferon- α) 231, 233
 IgA MGUS 19, 123
- IGF-1 (insulin-like growth factor-1) 65–67
 IgG MGUS 19, 123
IGH gene locus 24, 50, 190–191
 effect of translocations on cell cycle control 40–45
 IgM gammopathies
 cryoglobulinemia 193, 232–234, 246
 myeloma/MGUS 15, 24–25, 123, 245–246
 see also Waldenstrom
 macroglobulinemia
 I κ B kinases (IKKs) 71
 inhibitors 72
 IL-1 (interleukin-1) receptor
 antagonist (anakinra) 130, 236
 IL-1 β (interleukin-1 β) 99, 236
 IL-3 (interleukin-3) 99–100
 IL-6 (interleukin-6) 66, 74, 87
 anti-IL-6 therapies 66, 114, 221–222
 and bone disease 99
 in Castleman's disease 218–219, 221–222
 IL-7 (interleukin-7) 100
 IL-10 (interleukin-10) 87
 IL-17 (interleukin-17) 89
 imaging
 amyloidosis 175–176, 184
 cardiac involvement 177
 bone lesions 31–32, 97
 chest infections 278, 280, 282
 extramedullary plasmacytoma 170
 overview of various techniques 28–37
 POEMS syndrome 228
 in prognosis 29, 32, 127
 smoldering myeloma 127
 solitary bone plasmacytoma 32, 167–168
 Waldenstrom macroglobulinemia 197
 immune system
 dysfunctional aspects 84–90
 future areas for research 92–93
 in MGUS 86, 90–91
 response to tumor-associated antigens 90, 92
 risk factors for myeloma 7
 immunization
 infectious diseases 285
 tumor-derived targets 92
 immunoglobulins, intravenous
 see intravenous
 immunoglobulin therapy (IVIG)
 immunohistochemistry 12–13, 19
 immunomodulatory drugs
 see lenalidomide;
 pomalidomide; thalidomide

Index

- immunophenotyping
 amyloidosis 22, 175
 diagnosis 11–12
 extramedullary plasmacytoma 21, 170
 IgM myeloma 15
 MGUS 19, 123
 plasma cell leukemia 14–15
 POEMS syndrome 23
 prognosis 12–14, 19–20
 response assessment 25
 solitary bone plasmacytoma 20, 167
 t(11;14) myeloma 15
 therapeutic target identification 14
 Waldenstrom macroglobulinemia 24–25, 191, 196
- immunoproliferative small intestinal disease (α-HCD) 238
- immunotherapy 93
 graft-versus-myeloma effect 91–92
 immunization 92
 IVIG 84, 92, 231, 285
see also monoclonal antibody therapies
- incidence
 by age and sex 2, 4–5
 by geography/ethnicity 4–6
 long term trends 2–4
- indolent myeloma *see* smoldering myeloma
- infections 84–86, 92, 276–286
 bacterial 277–279, 285
 fungal 279–283, 285
 helminthic 284
 intestinal, in α-HCD 238
 myeloma as risk factor for infections 276
 iatrogenic 276–277
 neutropenia 277–279
 prophylaxis 84, 92, 284–286
 protozoal 284
 as risk factors for myeloma 7
 viral 283–285
 bortezomib and 84, 276–277
 in Castleman's disease 218–222
 in cryoglobulinemia 232–233
- infiltration, extent 11–12
- influenza 285
- INK4 proteins 40, 52
- insulin-like growth factor-1 (IGF-1) 65–67
- integrins/integrin receptors 68–69
- interferon-α (IFN-α) 231, 233
- interleukins (ILs)
 bone disease 99–100
 Castleman's disease 218–219, 221–222
 pathogenesis/progression of myeloma 66, 74, 87, 89, 130
- Schnitzler syndrome 236
- International Myeloma Working Group recommendations 36–37, 130
- intravenous immunoglobulin therapy (IVIG)
 for IgM neuropathy 231
 for infectious diseases 84, 92, 285
- invasive pulmonary aspergillosis (IPA) 280–281
- ionizing radiation as a risk factor 7–8
- IVIG *see* intravenous immunoglobulin therapy
- ixazomib 157
- Jagged ligand 76
- JAK/STAT signaling pathways 44, 74, 113
- Kaposi sarcoma 219
- KDIGO classification (kidney disease) 256
- kidney disease *see* renal disease
- kidney transplantation 262
- kinesin spindle protein inhibitor (ARRY-520) 158
- kinetin riboside 42
- Kyprolis (carfilzomib) 114, 157, 248, 268
- LCDD (light chain deposition disease) 236–237, 258–259
- Leishmania* infections 284
- lenalidomide
 adverse effects 138, 277
 amyloidosis 179
de novo myeloma
 induction pre-ASCT 134–135
 induction without ASCT 137–139
 maintenance post-ASCT 140
 maintenance without ASCT 140
 mode of action/targets 44, 91, 104
 peripheral neuropathy 247–248
 pharmacokinetics 265–266
 POEMS syndrome 230
 relapsed myeloma 153–154
 combination therapies 150–151, 153–154, 156, 158
 monotherapy 150
 renal disease 265–266
 smoldering myeloma 129–130, 169
 Waldenstrom macroglobulinemia 204
- lestaurtinib 54
- lichen myxedematosus (scleromyxedema) 234–235
- light chain deposition disease (LCDD) 236–237, 258–259
- liver disease
 amyloid 176–177, 183
 cryoglobulinemia 233
 viral hepatitis 284
- lucatumumab 114
- lung
 amyloid 184
 infections 276–278, 280–282
 POEMS syndrome 226–228
 Waldenstrom macroglobulinemia 195
- lymph node biopsy 197
- lymphoplasmacytic lymphoma (LPL) 23–24, 190
see also Waldenstrom macroglobulinemia
- macrophage inflammatory protein-1α (MIP-1α) 99
- macrophages 70
- MAG (myelin-associated glycoprotein), autoantibodies 193, 230, 245–246
- magnetic resonance imaging (MRI)
 31–33, 36
 cardiac amyloidosis 177
 PET/MRI 34–36
 prognosis of smoldering myeloma 127
 solitary bone plasmacytoma 32, 167–168
 Waldenstrom macroglobulinemia 197
- MALT (mucosa-associated lymphoid tissue) 238
- mantle cell lymphoma 15, 24
- MAPK signaling pathway(s) 77, 112
 inhibitors 110–111
- marginal zone lymphoma 24
- mast cells 191
- matrix metalloproteinases (MMPs) 64, 87
- MDCT (multidetector row CT) 29–30
- Mediterranean lymphoma (α-HCD) 238
- MEK inhibitors 74, 77, 110–111
- melfalan
 amyloidosis 178–180
de novo myeloma
 monotherapy 135
 plus bortezomib 137
 plus bortezomib and thalidomide 137
 plus lenalidomide 137–139
 plus prednisone only 137
 plus thalidomide 137
 POEMS syndrome 229
 relapsed myeloma
 combination therapies 153–154
 monotherapy 146

- smoldering myeloma 128–129
- meningitis, cryptococcal 282
- mesenchymal stem cells 69
- metastatic bone disease 29
- methylation
DNA 55, 58–60
histones 57–58
- methylprednisolone 145
- MGUS (monoclonal gammopathy of undetermined significance)
121–125
angiogenesis 124
diagnosis 11–12, 19, 32, 121
epidemiology 2, 4, 6–8, 48, 122, 124–125
fracture risk 125
genetics/gene expression profiles 25, 124
Ig profile 19, 122
IgM MGUS 24–25, 123, 245–246
immune response in 86, 90–91
immunophenotyping 19, 123
neuropathy 230–232, 245–246
progression 7, 19, 58, 121–123
high risk groups 12, 123
renal transplantation 262
thrombotic risk 125
treatment 125, 230–232
- MHC class I chain-related protein A (MICA) 91
- microarray analysis 55, 124
- microRNA 55
- migration of myeloma cells (into BM) 64–65
- milatuzumab 114
- Miller Fisher syndrome 194
- minimal residual disease (MRD) 13–14
- MIP-1 α (macrophage inflammatory protein-1 α) 99
- MLL* mutations 57
- MMPs (matrix metalloproteinases) 64, 87
- MMSET*/*MMSET* overexpression 40–41, 50, 57–58
- model systems 70
- mold infections 279–281, 285
- monoclonal antibody therapies
bone disease 103, 115
Castleman's disease 220–222
cryoglobulinemia 233
MGUS neuropathy 231–232
myeloma 14, 44, 92, 114–116
relapsed 158
POEMS syndrome 230
Waldenstrom macroglobulinemia 14, 200–205
- monoclonal gammopathy of undetermined significance
see MGUS
- motor nerve damage 245–246, 248
- motor neuron disease 194
- MRD (minimal residual disease) 13–14
- MRI *see* magnetic resonance imaging
- MRSA (meticillin-resistant *S. aureus*) 278
- mTOR signaling pathway 72–74, 77, 112–113
inhibitors 113, 202
- muc-1 glycoprotein 87
- mucormycosis 281
- mucosa-associated lymphoid tissue (MALT) 238
- multidetector row CT (MDCT) 29–30
- c-MYC* translocations 51
- myelin-associated glycoprotein (MAG), autoantibodies 193, 230, 245–246
- myeloma kidney (cast nephropathy) 256–259, 261–262, 268
- myeloma precursor cells 42–45
- natural killer (NK) cells 89–90
- neurobiotic xanthogranuloma (NXG) 235
- NEDD8-activating enzyme inhibition 72
- nematode infestations 284
- nephropathy *see* renal disease
- nephrotoxic drugs 103, 261
- neurological disorders
Bing-Neel syndrome 195
peripheral nerves *see* peripheral neuropathy
spinal cord compression 31, 96
- neutropenia 277–279
- newly diagnosed myeloma *see de novo* myeloma
- NF- κ B signaling pathway 52–54, 70–72, 75, 98–99
- NK cells (natural killer cells) 89–90
- non-hyperdiploid myeloma 50–51
see also translocations
- Notch signaling pathway 44, 75–76
- nuclear export protein (CRM1) inhibition 116–117
- nuclear medicine *see* radionuclide imaging; radiotherapy
- obesity 7
- ofatumumab 201
- ophthalmology *see* eye
- oprozomib 157–158
- osteoblasts 69
- inhibitory factors 99–101
therapies targeting 103–104, 115–116
- osteoclasts 69
- activating factors 96–99
therapies targeting 101–103, 115–116
- osteomyelitis 276
- osteonecrosis of the jaw 103
- osteoporosis 29, 125
- osteoprotegerin (OPG) 98–99
- osteosclerosis 29, 228
- osteosclerotic myeloma *see* POEMS syndrome
- pamidronate 101, 103, 129
- panobinostat 56, 116, 156–157
- papilledema 226
- paraproteins
antibody response to 90
in diagnosis 19
solitary bone plasmacytoma 167, 170
Waldenstrom macroglobulinemia 24
- pathogenesis 48–49
angiogenesis 68, 124, 217–218
bone disease 96–101
Castleman's disease 218–219
cell cycle control failure 40–42
cellular interactions in the BM 69–70, 88–90
cryoglobulinemia 232
epigenetics 55–60
genetics 49–55, 124, 190
heavy chain diseases 238
hypoxia in the BM 70
immune system dysfunction 86–90
MGUS neuropathy 230
neurobiotic xanthogranuloma 235
POEMS syndrome 226
renal disease 255–259
Schnitzler syndrome 236
scleromyxedema 234
soluble factors in the BM 64–69, 86–88
Waldenstrom macroglobulinemia 191
- PAX5 protein 12, 21
- PCP (*Pneumocystis jirovecii* pneumonia) 281–282, 285
- PCR (polymerase chain reaction) 13, 197, 279
- perifosine 73
- peripheral neuropathy 245–251
amyloidosis 176–177, 183–184, 246
chemotherapy-induced 246–251
clinical features 245–246
assessment and grading 249

Index

- peripheral neuropathy (cont.)
 chemotherapy-induced 247–248
 cryoglobulinemia 232–233, 246
 MGUS-associated IgM
 gammopathy 230–232,
 245–246
 POEMS syndrome 226, 228
 pre-existing, influence on myeloma
 treatment 249
 treatment 230–232, 245–246,
 249–250
 Waldenstrom macroglobulinemia
 193–194
- PET (positron emission tomography)
 34–37
 plasmacytoma 168, 170
 pharmacogenomics 200–201, 248–249
 PI3K/AKT signaling pathways 72–74,
 77, 112–113
 plasma cell leukemia (PCL) 14–15, 48,
 58–59
 plasma cell variant of Castleman's
 disease 218
 plasmacytoid dendritic cells 69–70, 88,
 92
 plasmacytoma *see* extramedullary
 plasmacytoma; solitary bone
 plasmacytoma
 plasmapheresis 231, 261
 Plerixafor (AMD300) 69
 pneumococcal infections 277–278
Pneumocystis jirovecii pneumonia
 (PCP) 281–282, 285
 POEMS syndrome 225–230
 bone marrow features 23, 228
 clinical presentation 29, 226–228
 cytogenetics 23
 polymerase chain reaction (PCR) 13,
 197, 279
 pomalidomide 91, 156–157, 179, 248
 posaconazole 285
 positron emission tomography (PET)
 34–37
 plasmacytoma 168, 170
 pre-malignant myeloma *see* MGUS
 (monoclonal gammopathy of
 undetermined significance)
 precursor cells 42–45
 prednisolone 150
 prednisone (combination therapies)
 Castleman's disease 220
de novo myeloma 137, 139–140
 relapsed myeloma 153–154
 smoldering myeloma 128–129
 Waldenstrom macroglobulinemia
 199, 202–203
- prognosis
 amyloidosis 22, 175–178, 246
 cryoglobulinemia 233
 cytogenetics 41, 52–53, 144, 175
 extramedullary plasmacytoma 171
 Fanconi syndrome 238
 flow cytometry 12–14, 19–20
 gene expression profiles 55
 imaging 29, 32, 127
 LCDD 237
 MGUS neuropathy 230–231
 MGUS progression 7, 19, 58,
 121–123
 high risk groups 12, 123
 MRD 13–14
 POEMS syndrome 228
 renal disease 266
 risk stratification for treatment
 choice 134
 Schnitzler syndrome 236
 smoldering myeloma progression
 125–128
 solitary bone plasmacytoma 20,
 169–170
 Waldenstrom macroglobulinemia
 197
- proteasomal inhibitors
 bortezomib *see* bortezomib
 carfilzomib 114, 157, 248, 268
 other 2nd generation 157–158
 target 72, 113–114
 protozoal infections 284
 pulmonary complications
 of amyloidosis 184
 of POEMS syndrome 226–228
 of Waldenstrom
 macroglobulinemia 195
 pulmonary infections 276–278,
 280–282
 purpura 184, 232
- race 6, 124
 radiography *see* computed
 tomography (CT); X-rays
 radionuclide imaging 33–36
 amyloidosis 175–177
 radiotherapy
 Castleman's disease 220
 extramedullary plasmacytoma 171
 planning 36
 POEMS syndrome 229
 solitary bone plasmacytoma 169
 RAF inhibitors 74
 RANKL/RANK signaling pathway
 98–99
 inhibitors 103, 115
 rapamycin 73–74
 RAS/RAF/MEK signaling pathways
 74, 77
 RAS mutations 54
 Raynaud phenomenon 232
 RBI deletion 53
- recurrence *see* relapsed/refractory
 myeloma
 registries 1–2
 regulatory T cells 88–89
 relapsed/refractory amyloidosis 181
 relapsed/refractory myeloma 144–158
 allogeneic transplant 155
 autologous transplant 154–155
 bortezomib and combinations
 148–149, 151–154, 156–157
 choice of treatment 144–145
 definition 144
 lenalidomide and combinations
 150–151, 153–154, 156, 158
 other drugs 145–146, 153, 155–158
 thalidomide and combinations
 146–150, 153
 renal disease 255–268
 amyloidosis 176–177, 181–183,
 258–259
 cast nephropathy 256–259,
 261–262, 268
 cryoglobulinemia 233
 diagnosis 255, 259–260
 Fanconi syndrome 237–238,
 258–260
 fibrillary glomerulonephritis 238
 infections and 276
 LCDD 236–237, 258–259
 nephrotoxic drugs 103, 261
 pathogenesis 255–259
 POEMS syndrome 227
 prognosis 266
 treatment
 in AKI 261–262, 268
 anti-myeloma therapies 262–268
 assessment of renal response
 260–261
 in CKD 261–268
 renal transplantation 262
 Waldenstrom macroglobulinemia 195
 respiratory tract *see* lung
 risk factors
 for infection 276–277
 for myeloma/MGUS 6–8, 124–125
 for Waldenstrom
 macroglobulinemia 190
 risk stratification in choice of therapy
 134, 144–145
 rituximab 14, 25, 44
 Castleman's disease 220–222
 cryoglobulinemia 233
 MGUS neuropathy 231–232
 Waldenstrom macroglobulinemia
 200–201
 combination therapies 202–204
 maintenance therapy 204–205
 RNA, post-transcriptional control 55
 romidepsin 157

- SBP *see* solitary bone plasmacytoma
- Schnitzler syndrome 195, 235–236
- scleromyxedema 234–235
- sclerostin 100
- SDF-1 (stromal-derived factor-1) 64–65, 69
- sensory nerve damage 245–246
chemotherapy-induced 247–248
- sepsis 277–278
- sex (epidemiology) 2, 4–5
- siltuximab 66, 114, 221–222
- SINEs (selective inhibitors of nuclear export) 117
- skeletal surveys 28–29
- skin conditions
in amyloidosis 184
in cryoglobulinemia 232
necrobiotic xanthogranuloma 235
in POEMS syndrome 226
Schnitzler syndrome 195, 235–236
scleromyxedema 234–235
in Waldenstrom
macroglobulinemia 195
- smoldering myeloma 125–130
definition/diagnostic criteria 48, 121, 125
epidemiology 1–2
genetic changes 41, 124
progression to myeloma 125–128
treatment 126, 128–130, 169
see also MGUS (monoclonal gammopathy of undetermined significance)
- solitary bone plasmacytoma (SBP) 20, 167–170
diagnosis and staging 20, 32, 167–168
prognosis/progression 20, 169–170
treatment 36, 168–169
see also extramedullary plasmacytoma
- sorafenib 74
- SOX11 protein 15
- spinal cord compression 31, 96
- spinal fractures 32
- splenic amyloid 183
- Staphylococcus aureus* infections 278
- STAT3 transcription factor 74
- stem cell transplantation *see* allogeneic stem cell transplantation;
autologous stem cell transplantation
- stem cells, myelomagenic (precursor cells) 42–45
- Streptococcus pneumoniae* infections 277–278
- stromal cells (BMSCs) 69, 71
- Strongyloides stercoralis* infections 284
- Suramin 221
- surgery
Castleman's disease 220
mold infections 281
solitary plasmacytomas 168–170
- survival times 4, 48
- syndecan-1 (CD138)
as a cell marker 11, 19–20
HGF and 68
- T cells
dysfunction 88–89, 92–93, 276
effect of immunomodulatory drugs 91
 $\gamma\delta$ T cell stimulation 88, 91
immune response to tumor-associated antigens 90
- t(4;14)(p16;q32) translocation 40–41, 50, 175
DNA methylation patterns 59
MMSET 40–41, 50, 57–58
- t(6;14)(p21;q32) translocation 50
- t(11;14)(q13;q32) translocation 13, 15, 40, 42, 50
- t(14;16)(q32;q23) translocation 50
- t(14;20)(q32;q21) translocation 50
- TACI-Fc (blocks APRIL) 68
- Takatsuki syndrome *see* POEMS syndrome
- Tamm-Horsfall protein 257
- targeted therapy 60, 110–111, 117–118
- TC (translocation and cyclin D) classification 55
- technetium-99m (Tc-99m) tracers
cardiac amyloidosis 177
myeloma 34
- TGF- β (transforming growth factor- β) 86, 101
- Th17 cells 89
- thalidomide
adverse effects 146, 277
peripheral neuropathy 246–247, 249
amyloidosis 179
Castleman's disease 221–222
de novo myeloma
consolidation post ASCT 139
induction pre-ASCT 134–135
induction without ASCT 137
maintenance post-ASCT 139–140
maintenance without ASCT 140
mode of action/targets 91, 104, 247
pharmacokinetics 264
relapsed myeloma 146, 148–149
combination therapies 148–150, 153
monotherapy 146–148
renal disease 264–265
smoldering myeloma 129
- Waldenstrom macroglobulinemia 202, 204
- thromboembolism risk 125, 184, 227, 277
- TNF *see* tumor necrosis factor (TNF) superfamily
- tocilizumab 221
- tocopherol (vitamin E) 250
- Toxoplasma gondii* infections 284
- TP53 deletion/mutation 52–54
- transcriptional control (epigenetic) 55–60
- transforming growth factor- β (TGF- β) 86, 101
- translational control (microRNA) 55
- translocations
acute myeloid leukemia 12
amyloidosis 22, 175
extramedullary plasmacytoma 21
myeloma 50–51
cell cycle control effects 41–45
DNA methylation patterns 59
gene expression profiles 55
t(4;14) 40–41, 50, 57–59
t(6;14) 50
t(11;14) 13, 15, 40, 42, 50
t(14;16) 50
t(14;20) 50
- transthyretin (ATTR) amyloidosis 174, 246
- treatment
amyloidosis 178–181, 183–185
bone disease 101–104, 115–116
Castleman's disease 220–222
choice of strategy 134, 144–145, 197–198, 220–221, 249
cryoglobulinemia 233–234
de novo myeloma *see de novo* myeloma
extramedullary plasmacytoma 170–171
Fanconi syndrome 238
FDA-approved targeted therapies 110–111, 114
heavy chain diseases
 α -HCD 238
 γ -HCD 239
 μ -HCD 239
infections
bacterial 84, 277–278, 285
fungal 279–282
Toxoplasma 284
viral 221, 233, 283
LCDD 237
MGUS 125, 230–232
necrobiotic xanthogranuloma 235
peripheral neuropathy 230–232, 245–246, 249–250
POEMS syndrome 228–230

Index

- treatment (cont.)
 relapsed myeloma *see* relapsed/
 refractory myeloma
 renal disease *see* renal disease,
 treatment
 response assessment 13–14, 32–34
 renal function improvement
 260–261
 in Waldenstrom
 macroglobulinemia 25, 197,
 206–207
 Schnitzler syndrome 236
 scleromyxedema 235
 smoldering myeloma 126, 128–130,
 169
 solitary bone plasmacytoma 36,
 168–169
 Waldenstrom macroglobulinemia
 14, 25, 116, 197–207
 tuberculosis 278
 tumor necrosis factor (TNF)
 superfamily
 APRIL/BAFF 67–68, 71, 88
 RANKL/RANK 98–99
 TNF- α 99
- ubiquitin 113–114
 urticaria 236
 UTX and histone methylation 57
- vaccination
 infectious diseases 285
 tumor-derived targets 92
 valganciclovir 221, 285
 varicella-zoster virus (VZV) 283, 285
- VEGF (vascular endothelial growth
 factor) 68, 87, 113
 Castleman's disease 217–218
 POEMS syndrome 226, 228–229
 Velcade *see* bortezomib
 vemurafenib (Zelboraf) 111
 vertebral fractures 32
 vincristine combination therapies
 Castleman's disease 220
de novo myeloma 134
 relapsed myeloma (VAD, M2) 145,
 154
 Waldenstrom macroglobulinemia
 202–203
- viral infections 283–284
 bortezomib and 84, 276–277
 HCV in cryoglobulinemia 232–233
 HHV8 in Castleman's disease
 218–219, 221
 HIV in Castleman's disease
 219–220, 222
 prophylaxis 285
 viscosity of serum/plasma
 (hyperviscosity syndrome)
 191–193, 196, 200
 vitamin supplements 250
 VLA-4/VLA-5 (CD49d/CD49e) 68–69
 voriconazole 281
 vorinostat 56, 116, 156
- WAF/CIP proteins 40
 Waldenstrom macroglobulinemia
 (WM) 23–25, 190–207
 bone marrow disease 23–24, 191,
 196–197
- clinical features 191–197
 compared with IgM myeloma/
 MGUS 15, 24–25
 cytogenetics 24–25, 190–191
 diagnosis 23–24, 196–197
 epidemiology 190
 hematological changes 194–197
 hyperviscosity syndrome
 191–193, 196, 200
 IgM
 measurement 196
 morbidities related to 191–195
 in prognosis 197
 after treatment 200, 206–207
 immunophenotype 24–25, 191, 196
 infiltration by neoplastic cells into
 other tissues 195
 pathogenesis 191
 prognosis 197
 transformation to DLBCL 25
 treatment 14, 116, 197–206
 response assessment 25, 197,
 206–207
 Wnt signaling pathway 75, 100, 104
 WWOX deletion 53
- X-rays 28–29
 bone lesions 97
 chest infections 278, 280, 282
 pulmonary amyloidosis 184
- yeast infections 282
- Zelboraf (vemurafenib) 111
 zoledronic acid 101–103, 129, 261